Several brokerages have updated their recommendations and price targets on shares of Amphastar Pharmaceuticals (NASDAQ: AMPH) in the last few weeks:

  • 10/22/2017 – Amphastar Pharmaceuticals was given a new $19.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 10/20/2017 – Amphastar Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
  • 10/19/2017 – Amphastar Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $21.00 price target on the stock. According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
  • 10/10/2017 – Amphastar Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
  • 9/27/2017 – Amphastar Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $18.00 to $20.00. They now have a “buy” rating on the stock.
  • 9/17/2017 – Amphastar Pharmaceuticals had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $19.00 price target on the stock.

Amphastar Pharmaceuticals, Inc. (NASDAQ AMPH) traded down 0.05% during mid-day trading on Tuesday, reaching $18.25. The company’s stock had a trading volume of 162,198 shares. The company’s 50-day moving average price is $17.33 and its 200 day moving average price is $16.50. Amphastar Pharmaceuticals, Inc. has a 52 week low of $12.05 and a 52 week high of $21.75. The firm has a market capitalization of $843.06 million, a price-to-earnings ratio of 237.01 and a beta of 1.69.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, August 9th. The company reported $0.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.05. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The firm had revenue of $65.20 million during the quarter, compared to the consensus estimate of $63.40 million. During the same quarter last year, the firm earned $0.23 EPS. The firm’s revenue for the quarter was down 4.1% on a year-over-year basis. On average, equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post $0.27 earnings per share for the current fiscal year.

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $14.80, for a total value of $74,000.00. Following the completion of the transaction, the director now owns 33,844 shares of the company’s stock, valued at approximately $500,891.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $14.81, for a total transaction of $148,100.00. Following the completion of the transaction, the director now directly owns 33,844 shares of the company’s stock, valued at approximately $501,229.64. The disclosure for this sale can be found here. Insiders sold a total of 145,653 shares of company stock valued at $2,626,205 in the last three months. 11.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Receive News & Ratings for Amphastar Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.